The Global Journal of Infectious Diseases and Immune Therapies is an international, peer-reviewed, open-access journal dedicated to publishing the most recent advances in Infectious Diseases and Immunotherapies. Researchers and practitioners participate in GJIDIT to discuss the latest developments in the theory and practice of infection epidemiology, diagnosis, and treatment, antibiotics, and resistance.
Using Pubtexto's open-access platform, scholars and doctors can get the latest information on the latest scientific developments, applications, and data interpretation in clinical and preclinical research. In addition to providing original articles, reviews, and case reports on the latest discoveries and developments related to all areas of medicine, Pubtexto is committed to bringing comprehensive and reliable information on the latest developments. Researchers can use Pubtexto to share their innovative ideas and work and to recognize their scholarly works. In this knowledge dissemination process, students, librarians, scholars, research centers, educational institutions and research centers get the most significant benefit.
The journal emphasizes the managerial and organizational facets of studies prevail to infectious diseases and immune therapies focusing on the origin of the infectious organism, pathogenesis related to the causative organism, diagnosis of the disease by various diagnostic products, preventing the spreading of these vulnerable diseases by vaccination, Immunology, etiopathogenesis, antibiotic resistance, pharmacoeconomics, prognosis, patient care, counseling, and education of the new innovations and advanced therapies.
GJIDIT's goal is to provide the most complete and reliable source of information on the latest discoveries and developments. We encourage the submission of manuscripts that meet the general criteria of significance and scientific excellence. GJIDIT journal seeks to publish a balanced mix of high-quality theoretical or Empirical research articles, Reviews, Case reports, Editorial, short communication, Letter to the editor, Commentary, book reviews, etc.,
Frequency: Quarterly
Review Process: Double-blinded peer review process
Plagiarism Policy
The articles submitted by authors must contain a minimum of 80% unique content (Which should be unique and must not copy from any other websites). The authors must maintain 100% uniqueness in the Results and conclusion part of the text. We will resend the articles, which have below 80% uniqueness to the authors for revision and ask for resubmissions with uniqueness (as per guidelines).
Authors are welcome to submit their manuscript online at Submit Manuscript Or as an email attachment to editor8infectious@gmail.com
Global Journal of Infectious Diseases and Immune Therapies (GJIDIT) features a vast spectrum of topics that address the clinical and medical aspects of the disease by including studies on Infectious Diseases, Immune deficiencies, Sexually Transmitted Diseases (STD), Gynecology, Clinical virology, Epidemiology, Molecular biology, and Immunology. Apart from focusing on the research that finds ways and means to fight the disease, the journal pays attention to the social stigma attached to the disease by focusing on studies related to HIV Medicine, HIV Drug therapies, Behavioral Sciences, Social sciences & Humanities, AIDS Education & Prevention, family Medicine, Translational Science, etc…
The journal covers a wide range of topics in this discipline and creates a platform for the authors to contribute to the advancement of Infectious Diseases Knowledge.
The desire of the journal is to advance the knowledge and clinical practice in all the interdisciplinary areas of Infectious Diseases and Immunotherapies. This journal strives to serve a diverse readership by publishing articles on a range of topics but not limited to
A | B | C |
Adult (Non-Flu) Vaccines | Bacterial infections | Campylobacter |
Agriculture Biosecurity | Biosecurity Issues | Chikungunya |
Antimicrobial resistance | Babesiosis | Childhood Vaccines |
Acute Flaccid Myelitis | Botulism | Cancer immunotherapy |
Anaplasmosis | Brucellosis | Cholera |
Anthrax | Bioterrorism | Campylobacteriosis |
Autoimmune diseases | Botulism | Carbapenem-resistant Infection |
Antimicrobial Stewardship | Bse | Chancroid |
Avian Influenza (Bird Flu) | Business Preparedness | Chikungunya Virus Infection |
D | E | Chlamydia |
Diagnostic Immunology | E Coli | Ciguatera Clostridium Difficile Infection |
Dengue | Ebola | Chronic infection |
Dengue, 1,2,3,4 (Dengue Fever) | Encephalopathy | Clostridium Perfringens |
Diphtheria Diagnostics | Shiga toxin-producing (STEC) Eastern Equine Encephalitis (EEE) | Coccidioidomycosis fungal infection |
Drug Supply Chains | Ebola Hemorrhagic Fever (Ebola) | Creutzfeldt-Jacob Disease, transmissible spongiform Clinical Immunology |
Dual-Use Research | Ehrlichiosis | Climate Change |
F | Encephalitis, Arboviral or parainfectious | Clostridium Difficile |
Food Biosecurity | Enterovirus Infection, Non-Polio (Non-Polio Enterovirus) | Cryptosporidiosis |
Foodborne Disease | Enterovirus Infection, D68 (EV-D68) | Cyclosporiasis |
Foot-And-Mouth Disease | Enterovirus, Non-Polio | COVID-19 |
Fungal Infection | Epidemiology | Computational Immunology |
G | H | L |
Giardiasis (Giardia) | H1n1 2009 Pandemic Influenza | Legionella |
Glanders | Hepatitis | Listeria |
Gonococcal Infection | H3n2v Influenza | M |
Granuloma inguinale | Haemophilus Influenza disease, Type B (Hib or H-flu) | Malaria |
Glanders & Melioidosis | Hantavirus Pulmonary Syndrome | Mycotic infections |
I | Hemolytic Uremic Syndrome (HUS) | Meningitis |
Influenza (Flu) | Hepatitis A (Hep A) | Malaria |
Immunopathogenesis | Hepatitis B (Hep B) | Measles |
Influenza Vaccines | Hepatitis C (Hep C) | Melioidosis |
Immunology | Hepatitis D (Hep D) | Meningitis, Viral (Meningitis, viral) |
Influenza, General | Hepatitis E (Hep E) | Meningococcal Disease, Bacterial |
Influenza virus | Herpes | Middle East Respiratory Syndrome Coronavirus |
Intestinal diseases | Herpes Zoster, zoster VZV (Shingles) | Multisystem Inflammatory Syndrome in Children |
Infectious diseases | Histoplasmosis infection (Histoplasmosis) | Mumps Marburg |
Q-Fever | Human Immunodeficiency Virus/AIDS (HIV/AIDS) | Mcr-1 |
N | Human Papillomavirus (HPV) | Measles |
Ndm-1 | H7n9 Avian Influenza | Melioidosis |
Neonatal sepsis | Helicobacter pylori | Meningitis |
Norovirus | HIV infections | Mers-Cov |
Novel Coronavirus | Healthcare-Associated Infections | Misc Emerging Topics |
R | Hemolytic Uremic Syndrome (Hus) | Mrsa |
Rinderpest | Human Papillomavirus (Hpv) | Mumps |
Rotavirus | T | V |
Rubella | Transmissive or blood infections | Vaginosis, bacterial (Yeast Infection) |
P | Tick-Borne Disease | Vaping-Associated Lung Injury |
Public Health | Tetanus Infection, tetani (Lock Jaw) | Varicella (Chickenpox) |
Pandemic and epidemic diseases | Trichomoniasis (Trichomonas infection) | Vibrio cholerae (Cholera) |
Pandemic Influenza | Trichonosis Infection (Trichinosis) | Vibriosis (Vibrio) |
Pediatric Infectious Diseases | Tularemia (Rabbit fever) | Viral Hemorrhagic Fever |
Parasitic infection | Typhoid Fever, Group D | Viral infections |
Plague | Typhus Testicular Immunology | Viral Immunology |
Pneumonia | Tuberculosis | W |
Polio | Tularemia | West Nile Virus |
Pathogen cell biology | Y | |
S | Yersenia (Yersinia) | |
Salmonella | Yellow Fever | |
Sars | Z | |
Scombroid | Zika Virus Infection (Zika) | |
Septic Shock (Sepsis) | ||
Severe Acute Respiratory Syndrome (SARS) Shigellosis gastroenteritis (Shigella) | ||
Staphyloccal Infection | ||
Methicillin-resistant | ||
Staphylococcal Food Poisoning, Enterotoxin - B Poisoning (Staph Food Poisoning) | ||
Staphylococcal Infection, | ||
Vancomycin Intermediate | ||
Staphylococcal Infection, Vancomycin Resistant | ||
Streptococcal Disease, Group A (invasive) (Strep A (invasive)) | ||
Streptococcal Disease, Group B (Strep-B) Streptococcal Toxic-Shock Syndrome, STSS, Toxic Shock (STSS, TSS) | ||
Syphilis, primary, secondary, early latent, late latent, congenital | ||
Smallpox | ||
Swine Influenza |